<code id='7A0506FE10'></code><style id='7A0506FE10'></style>
    • <acronym id='7A0506FE10'></acronym>
      <center id='7A0506FE10'><center id='7A0506FE10'><tfoot id='7A0506FE10'></tfoot></center><abbr id='7A0506FE10'><dir id='7A0506FE10'><tfoot id='7A0506FE10'></tfoot><noframes id='7A0506FE10'>

    • <optgroup id='7A0506FE10'><strike id='7A0506FE10'><sup id='7A0506FE10'></sup></strike><code id='7A0506FE10'></code></optgroup>
        1. <b id='7A0506FE10'><label id='7A0506FE10'><select id='7A0506FE10'><dt id='7A0506FE10'><span id='7A0506FE10'></span></dt></select></label></b><u id='7A0506FE10'></u>
          <i id='7A0506FE10'><strike id='7A0506FE10'><tt id='7A0506FE10'><pre id='7A0506FE10'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:hotspot    Page View:1
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

          DarronCummings/APEliLillysaidTuesdaythatitwillpurchaseDICETherapeutics,asmallcompanydevelopinganexpe

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          How digital tools helped lower hypertension in marginalized patients

          Digitaltoolstobettertrackbloodpressureovertimeandencourageadherencetotreatmentplansareincreasinglyco